Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents

  title={Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents},
  author={Danuta Marona-Lewicka and David E. Nichols},
Abstract MMAI (5-methoxy-6-methyl-2-aminoindan) is a nonneurotoxic, highly selective neuronal serotonin (5-HT) releasing agent. MMAI and other 5-HT releasing agents produce a robust discriminative cue in drug discrimination (DD) studies. The selective serotonin reuptake inhibitors (SSRIs) sertraline and citalopram may also serve as discriminative stimuli, but acquisition of their discrimination required almost twice as much time as for MMAI. In vitro, 5-HT release by MMAI can be blocked by… 

The discriminative stimulus properties of LY233708, a selective serotonin reuptake inhibitor, in the pigeon

It is demonstrated that an SSRI can induce a specific, stable discriminative stimulus that appears to involve activation of the 5-HT1A receptor in the pigeon.

5-HT2C receptors are involved in the discriminative stimulus effects of citalopram in rats

It is suggested that 5-HT2C receptors are involved in the DS properties of the SSRI, citalopram, in rats, which does not, however, exclude a potential role of other 5- HT receptor types.

Discriminative stimulus properties of tianeptine

The discriminative stimulus effect of tianeptine is mediated by serotonergic mechanisms, but what is surprising is that this mechanism seems to be, at least partially, enhanced bySerotonergic transmission.

Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats: a characterization with alpha/beta-adrenoceptor subtype selective ligands, antidepressants, and antagonists at neuropeptide receptors.

  • M. MillanA. Dekeyne
  • Biology, Psychology
    The international journal of neuropsychopharmacology
  • 2007
DS properties of reboxetine are mimicked by antidepressants recognizing NE transporters, and require functionally intact alpha1-ARs for their expression.

Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats

In parallel with an elevation in extracellular levels of NE, the selective NE reuptake inhibitor, reboxetine, elicits a specific discriminative stimulus in rats.

Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats

The results demonstrate that the cellular actions of the individual channel-blocking NMDA antagonists, in particular affinity for the channel site and NMDA receptor specificity, are important determinants of their discriminative stimulus effects.



Imipramine as a discriminative stimulus.

  • L. ZhangJ. Barrett
  • Psychology, Biology
    The Journal of pharmacology and experimental therapeutics
  • 1991
This appears to be the first report of the successful, long-term establishment of imipramine as a discriminative stimulus without the development of toxicity and confirms reports that compounds active at this receptor site may have antidepressant activity.

Paroxetine, a Selective 5‐Hydroxytryptamine Uptake Inhibitor with Antidepressant Properties, Lacks Amphetamine‐like Stimulus Properties in an Operant Drug Discrimination Bioassay in Rodents *

The data confirm earlier studies which suggested that some antidepressants may possess abuse potential because of their ability to induce amphetamine‐like internal states, while paroxetine is devoid of such properties.

Preferential Potentiation of the Effects of Serotonin Uptake Inhibitors by 5‐HT1A Receptor Antagonists in the Dorsal Raphe Pathway: Role of Somatodendritic Autoreceptors

The data suggest that dorsal raphe neurons projecting to striatum and frontal cortex are more sensitive to self‐inhibition mediated by 5‐HT1A autoreceptors than median raphe cells projecting to the hippocampus, which occurs preferentially in forebrain areas innervated by serotonergic neurons of the dorsal Raphe nucleus.

Interaction between a selective 5‐HT1A receptor antagonist and an SSRI in vivo: effects on 5‐HT cell firing and extracellular 5‐HT

Pretreatment with the selective 5‐HT1A receptor antagonist, WAY 100635, blocked the inhibitory effect of paroxetine on5‐HT neuronal activity in the DRN and, at the same time, markedly enhanced the effect ofParoxetines on extracellular 5‐ HT in the FCx.

Non-neurotoxic amphetamine derivatives release serotonin through serotonin transporters.

Two non-neurotoxic derivatives of MDMA were tested in membrane vesicle model systems to determine whether they also lacked the ability to release serotonin, and although MMAI effects on the serotonin transporter were similar to those of MDMA, the two compounds had different effects on dopamine transporters.

Occupancy of the serotonin transporter by fluoxetine, paroxetine, and sertraline: In vivo studies with [125i]rti‐55

The results indicate that in competition studies, [125I]RTI‐55 can be used to identify doses of drugs that are physiologically effective, to determine their relative rate of occupancy, and most importantly, to measure the residency time on the central serotonin transporter in vivo.